论文部分内容阅读
目的 :观察阿尔马尔治疗原发性震颤的疗效和安全性。方法 :采用多中心开放试验 ,对 3 2例原发性震颤患者给予阿尔马尔 10mg ,每日 1次 ,共 4周。对疗效不好者 ,从第 3周开始增加剂量至 2 0mg ,每日 2次 ,共计 6周。于治疗前和治疗后第 2 ,4,6周进行症状评分。结果 :阿尔马尔治疗原发性震颤的总有效率为 78 1% ,对正常的血压和心率无明显影响 ,不良反应较微。结论 :阿尔马尔是治疗原发性震颤的有效药物 ,服用方便而且安全。
Objective: To observe the efficacy and safety of Almar in the treatment of essential tremor. Methods: In a multicenter open-label trial, 32 patients with essential tremor were given Almar 10 mg once daily for 4 weeks. On the poor efficacy, starting from the third week to increase the dose to 20mg twice daily for a total of 6 weeks. Symptom scores were assessed before treatment and at 2, 4 and 6 weeks after treatment. Results: The total effective rate of Almar in the treatment of essential tremor was 78.1%, with no significant effect on normal blood pressure and heart rate with minor adverse reactions. Conclusion: Almar is an effective drug for the treatment of essential tremor and is convenient and safe to take.